Gradual Expansion of the CRO and CSO Markets
First written in FY2017-Q1. 15 of 16 entries say "Restated". Latest entry: FY2023-Q2.
2 other companies' latest entry also says "Restated".
- FY2023-Q2RestatedAnnual report
「Demand for clinical trials from overseas pharmaceutical-related companies, particularly in Europe and the United States, remains strong, and the order backlog remains at a high level.」
The current assessment that demand for clinical trials from overseas pharmaceutical-related companies, particularly in Europe and the United States, is strong and the order backlog remains at a high level is described. - FY2021-Q2RestatedAnnual report
「Although the CRO industry in which the Group operates is expected to be affected by the spread of COVID-19 in the short term, the market is expected to expand moderately over the long term, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note). Pharmaceutical companies are also expected to promote the outsourcing of pharmaceutical development to create innovative drugs and further improve productivity and efficiency.」
The view that, while acknowledging the short-term impact of infectious diseases, the CRO market will expand moderately over the long term and outsourcing of pharmaceutical development will advance is reaffirmed. - FY2021-Q1RestatedAnnual report
「The contract research organization (CRO) industry in which the Group operates is expanding moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note). In light of the conditions in the pharmaceutical industry described above, pharmaceutical companies are expected to further accelerate the outsourcing of pharmaceutical development to create innovative drugs and further improve productivity and efficiency.」
The moderate expansion of the CRO market and the outlook for further acceleration in pharmaceutical companies' outsourcing of pharmaceutical development continue to be described. - FY2020RestatedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates are expanding moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note). In light of the conditions in the pharmaceutical industry described above, pharmaceutical companies are expected to further accelerate the outsourcing of pharmaceutical development and sales to create innovative drugs and further improve productivity and efficiency.」
The moderate expansion of the CRO and CSO markets and the outlook for further acceleration in pharmaceutical companies' outsourcing are reaffirmed. - FY2020-Q1RestatedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates are expanding moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note). In light of the conditions in the pharmaceutical industry described above, pharmaceutical companies are expected to further accelerate the outsourcing of pharmaceutical development and sales to create innovative drugs and further improve productivity and efficiency.」
The moderate expansion of the CRO and CSO markets and the outlook for further acceleration in pharmaceutical companies' outsourcing of pharmaceutical development and sales are reaffirmed. - FY2019-Q3RestatedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates are expanding moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note). In light of the conditions in the pharmaceutical industry described above, pharmaceutical companies are expected to further accelerate the outsourcing of pharmaceutical development and sales to create innovative drugs and further improve productivity and efficiency.」
The moderate expansion of the CRO and CSO markets and the outlook for further acceleration in pharmaceutical companies' outsourcing of pharmaceutical development and sales are reaffirmed. - FY2019-Q2RestatedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates are expanding moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note). In light of the conditions in the pharmaceutical industry described above, pharmaceutical companies are expected to further accelerate the outsourcing of pharmaceutical development and sales to create innovative drugs and further improve productivity and efficiency.」
The moderate expansion of the CRO and CSO markets and the outlook for further acceleration in pharmaceutical companies' outsourcing of pharmaceutical development and sales are reaffirmed. - FY2019-Q1RestatedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates are expanding moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note). In light of the conditions in the pharmaceutical industry described above, pharmaceutical companies are expected to further accelerate the outsourcing of pharmaceutical development and sales to create innovative drugs and further improve productivity and efficiency.」
The outlook for further acceleration in pharmaceutical companies' outsourcing of pharmaceutical development and sales, in addition to the moderate expansion of the CRO and CSO markets, is described. - FY2018RestatedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates are expanding moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note).」
The moderate expansion of the CRO and CSO markets, driven by increasing outsourcing and growth in international joint clinical trials, is reaffirmed, and further acceleration of outsourcing is expected going forward. - FY2018-Q3RestatedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates are expanding moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note).」
The moderate expansion of the CRO and CSO markets, driven by increasing outsourcing and growth in international joint clinical trials, is reaffirmed. - FY2018-Q2RestatedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates are expanding moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note).」
The moderate expansion of the CRO and CSO markets, driven by increasing outsourcing and growth in international joint clinical trials, is reaffirmed. - FY2018-Q1RestatedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates continued to expand moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note).」
The moderate expansion of the CRO and CSO markets, driven by increasing outsourcing and growth in international joint clinical trials, is reaffirmed. - FY2017RestatedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates are expanding moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note).」
The moderate expansion of the CRO and CSO markets, driven by increasing outsourcing and growth in international joint clinical trials, is reaffirmed. - FY2017-Q3RestatedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates are expanding moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note).」
The moderate expansion of the CRO and CSO markets, driven by increasing outsourcing and growth in international joint clinical trials, is reiterated. - FY2017-Q2RestatedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates are expanding moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note).」
The moderate expansion of the CRO and CSO markets, driven by increasing outsourcing and growth in international joint clinical trials, is reiterated. - FY2017-Q1First statedAnnual report
「The contract research organization (CRO) and contract sales organization (CSO) industries in which the Group operates continued to expand moderately, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials (Note).」
The structural trend of moderate expansion in the CRO and CSO markets, driven by the increasing outsourcing of pharmaceutical development and sales and the growth in international joint clinical trials, is described.